Abstract 1224P
Background
Lung cancer remains the leading cause of cancer-related death worldwide. In selected cases, treatment of resected Non-Small Cell Lung Cancer (NSCLC) requires in adjuvant chemotherapy. However, no guidelines are available for adjuvant chemotherapy in patients over 75 years-old by lack of dedicated studies. In this study, we assessed the benefit of adjuvant chemotherapy in patients over 75 years-old with NSCLC.
Methods
We conducted a single centre retrospective study in Marseille University Hospital based on the prospective EPITHOR database, including all patients over 75 years-old with NSCLC who underwent a complete lung anatomical surgical resection, with a theorical indication for adjuvant chemotherapy between January 2013 and July 2022. We compared survival outcomes of patients undergoing adjuvant chemotherapy or not. Primary outcome was 5 years disease-free survival (DFS) (Fine and Gray model, 5-years relapse rate being the competitive event) and secondary objectives was overall survival.
Results
129 patients were eligible for our study, 36 in the adjuvant chemotherapy group and 93 in the control group. Patients treated with adjuvant chemotherapy appeared to be younger, have a favourable perioperative course and a positive post-operative lymph node status. Adjuvant chemotherapy was significantly related to 5-years DFS in univariate analysis (HR=0.257 [95% CI: 0.080-0.819] p=0.0216) but not in multivariate analysis (HR=0.641 [95% CI: 0.144-1.473] p=0.191).Adjuvant chemotherapy was related to a lower mortality in univariate analysis (HR=0.567 [95% CI: 0.312-1.031] p=0.0631) but in multivariate analysis, chemotherapy did not seem to be related with cancer relapse or death (HR = 1.284 [95% CI: 0.72-2.28], p=0.40). Multivariate model included comorbidity index, age and VEMS.
Conclusions
Within daily care, oncologists tend to propose adjuvant chemotherapy on a patient-by-patient basis according to their post-operative lymph node status and comorbidities. This study provides a scientific basis for these choices and suggests that adjuvant chemotherapy benefit must be balanced considering specific geriatric comorbidities. Further studies will be needed to set up dedicated guidelines.
Clinical trial identification
PADS23-151.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Mogenet: Financial Interests, Institutional, Advisory Board: Pfizer, Takeda, AstraZeneca; Financial Interests, Institutional, Other, Travel fee: BMS; Financial Interests, Institutional, Invited Speaker: Takeda, Viatris. A. Couderc: Financial Interests, Institutional, Speaker, Consultant, Advisor: BMS, Ferrring, Nutricia, Amgen, Sanofi, GSK. P. Tomasini: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, BMS, Lilly, Janssen, Amgen, Takeda; Financial Interests, Institutional, Local PI: Roche, AstraZeneca, Amgen, Lilly, Takeda; Financial Interests, Institutional, Coordinating PI: Janssen. L. Greillier: Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, BMS, MSD, Novartis, Sanofi, Takeda, Roche; Financial Interests, Personal, Invited Speaker: Lilly, Pfizer; Financial Interests, Institutional, Local PI: AstraZeneca, AbbVie, BMS, MSD, Novartis, Takeda, Pfizer, Roche, PharmaMar; Financial Interests, Institutional, Coordinating PI: Sanofi. J. Pluvy: Financial Interests, Personal, Invited Speaker: Sanofi, Roche, Takeda, AstraZeneca, Viatris; Financial Interests, Personal, Advisory Board: Takeda, Sanofi. P.A. Thomas: Financial Interests, Institutional, Speaker, Consultant, Advisor: AstraZeneca, BMS, Roche, MSD, Amgen; Financial Interests, Institutional, Advisory Board: Ethicon. All other authors have declared no conflicts of interest.
Resources from the same session
1121P - Artificial Intelligence to predict BRAF mutational status from whole slide images in melanoma
Presenter: Céline Bossard
Session: Poster session 04
1122P - The role of imaging during follow-up after radical surgery of stage IIb-c and III cutaneous malignant melanoma: Survival results from an interim analysis of a randomized prospective multicenter study (TRIM)
Presenter: Cecilia Ladjevardi
Session: Poster session 04
1123P - Melanoma incidence and mortality decline in younger adults in Sweden: Start of a shift in the upgoing trend?
Presenter: Hildur Helgadottir
Session: Poster session 04
1124P - Adjuvant treatment of patients with stage III melanoma: 4-year follow-up time of multicenter real-world study
Presenter: Elisabeth Livingstone
Session: Poster session 04
1125P - Accuracy of PET-CT to assess extent of nodal disease in clinical stage III melanoma
Presenter: Ronen Stoff
Session: Poster session 04
1126P - A phase II study of nivolumab/relatlimab in metastatic uveal melanoma
Presenter: Jose Lutzky
Session: Poster session 04
1127P - Subgroup analysis of FOCUS phase III trial efficacy results
Presenter: Matthew Wheater
Session: Poster session 04
1128P - Preliminary results of first-in-human study of 225-Actinium MTI-201 (225Ac-MTI-201) in metastatic uveal melanoma
Presenter: Nikhil Khushalani
Session: Poster session 04
1129P - Clinical outcomes from a tebentafusp UK expanded access program in patients with metastatic uveal melanoma (mUM)
Presenter: Paul Nathan
Session: Poster session 04
1130P - Phase II trial on nivolumab plus radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trial
Presenter: Motoo Nomura
Session: Poster session 04